• レポートコード:TPM-2JN062 • 出版社/出版日:Transparency Market Research / 2019年11月29日 • レポート形態:英文、PDF、184ページ • 納品方法:Eメール • 産業分類:医療 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは遺伝性血管浮腫治療の世界市場について調査・分析し、序論、仮定・研究方法、エグゼクティブサマリー、市場状況、市場動向、薬物クラス別分析、投与経路別分析、流通経路別分析、エンドユーザー別分析、地域別(北米、欧州、その他の地域)分析、競争状況などを含め、次の構成でお届けいたします。 ・序論 ・仮定・研究方法 ・エグゼクティブサマリー ・市場状況 ・市場動向 ・遺伝性血管浮腫治療の世界市場:薬物クラス別 ・遺伝性血管浮腫治療の世界市場:投与経路別 ・遺伝性血管浮腫治療の世界市場:流通経路別 ・遺伝性血管浮腫治療の世界市場:エンドユーザー別 ・遺伝性血管浮腫治療の世界市場:地域別(北米、欧州、その他の地域) ・遺伝性血管浮腫治療の北米市場分析・予測 ・遺伝性血管浮腫治療の欧州市場分析・予測 ・遺伝性血管浮腫治療のその他の地域市場分析・予測 ・競争状況 |
The prevalence of rare diseases has surged in recent years, as the tracking of their incidence has improved around the world in the past few decades. This is particularly significant for genetic diseases, as standardized screenings and tests are few, as such, making it hard to determine how many people are affected by them. Hereditary angioedema, also known as HAE, has been in the spotlight, as government and non-government organizations around the world work to raise public awareness to increase diagnosis and improve treatment. According to a report by Transparency Market Research on the global hereditary angioedema treatment market, in 2018, the treatment for HAE was sought mainly in North America, making it the largest regional market, accounting for over three-fourth of the global market share. This can be attributed not only to enhanced data tracking, but also better healthcare infrastructure, which has led to the better availability of specialty HAE products in the region.
Although the North America market is expected to grow at a healthy pace over the forecast years, it is expected to yield market share of ~4% to Europe and the Rest of the World, as public awareness about the disease rises in other parts of the world, shaping the further evolution of the hereditary angioedema treatment market.
The intravenous route of medicine administration has been the method of choice for drugs used in the treatment of hereditary angioedema. This can be attributed to the fact that, conventional prophylactic drugs have traditionally been administered intravenously, and this method has occupied a significant share of the global hereditary angioedema treatment market in the last few years. However, with the development of drugs that can be administered orally and by subcutaneous injection, intravenous drugs are expected to lose popularity in the foreseeable future.
The phenomenal growth of subcutaneous injections as a mode of drug administration can be attributed to the demand for ease-of-usage for patients, which has had an instrumental impact on the growth of this segment. Where in 2018 subcutaneous injections accounted for close to half of the total market, by the end of the forecast period in 2027, this segment is anticipated to grow to occupy ~65% of the share.
In recent years, there has been an impressive amount of research being done for the development of drugs for hereditary angioedema treatment. This has included not just drugs to control the symptoms of the illness, but also prophylactic treatment for HAE attacks. There are currently several drugs that are in various stages of approval for the long-term prophylactic treatment of HAE in children and adults. For instance, in May 2019, BioCryst Pharmaceuticals announced that its drug – BCX7353, for the prevention of (HAE) attacks, has achieved its primary endpoint for both dose levels.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hereditary Angioedema Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Pipeline Analysis
5.2. Orphan Drug Exclusivity Scenario
5.3. Key Merger & Acquisitions
5.4. Disease Overview
5.5. Disease Prevalence-Global and Key Countries
6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. C1 Esterase Inhibitor
6.3.1.1. Plasma Products
6.3.1.1.1. Berinert
6.3.1.1.2. Cinryze
6.3.1.1.3. Haegarda
6.3.1.2. Recombinant Products
6.3.1.2.1. Ruconest
6.3.2. Selective Bradykinin B2 Receptor Antagonist
6.3.2.1. Firazyr
6.3.3. Kallikrein Inhibitor
6.3.3.1. Kalbitor
6.3.3.2. Takhzyro
6.3.4. Others
6.3.4.1. Conventional Drugs
6.3.4.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Class
7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2027
7.3.1. Intravenous
7.3.2. Subcutaneous Injection
7.3.3. Oral
7.4. Market Attractiveness, by Route of Administration
8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel
9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Rest of the World
9.3. Market Attractiveness, by Country/Region
10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. C1 Esterase Inhibitor
10.2.1.1. Plasma Products
10.2.1.1.1. Berinert
10.2.1.1.2. Cinryze
10.2.1.1.3. Haegarda
10.2.1.2. Recombinant Products
10.2.1.2.1. Ruconest
10.2.2. Selective Bradykinin B2 Receptor Antagonist
10.2.2.1. Firazyr
10.2.3. Kallikrein Inhibitor
10.2.3.1. Kalbitor
10.2.3.2. Takhzyro
10.2.4. Others
10.2.4.1. Conventional Drugs
10.2.4.2. Pipeline Drugs
10.3. Market Value Forecast, by Route of Administration, 2017–2027
10.3.1. Intravenous
10.3.2. Subcutaneous Injection
10.3.3. Oral
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
11.1. .Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. C1 Esterase Inhibitor
11.2.1.1. Plasma Products
11.2.1.1.1. Berinert
11.2.1.1.2. Cinryze
11.2.1.1.3. Haegarda
11.2.1.2. Recombinant Products
11.2.1.2.1. Ruconest
11.2.2. Selective Bradykinin B2 Receptor Antagonist
11.2.2.1. Firazyr
11.2.3. Kallikrein Inhibitor
11.2.3.1. Kalbitor
11.2.3.2. Takhzyro
11.2.4. Others
11.2.4.1. Conventional Drugs
11.2.4.2. Pipeline Drugs
11.3. Market Value Forecast, by Route of Administration, 2017–2027
11.3.1. Intravenous
11.3.2. Subcutaneous Injection
11.3.3. Oral
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. C1 Esterase Inhibitor
12.2.1.1. Plasma Products
12.2.1.1.1. Berinert
12.2.1.1.2. Cinryze
12.2.1.1.3. Haegarda
12.2.1.2. Recombinant Products
12.2.1.2.1. Ruconest
12.2.2. Selective Bradykinin B2 Receptor Antagonist
12.2.2.1. Firazyr
12.2.3. Kallikrein Inhibitor
12.2.3.1. Kalbitor
12.2.3.2. Takhzyro
12.2.4. Others
12.2.4.1. Conventional Drugs
12.2.4.2. Pipeline Drugs
12.3. Market Value Forecast, by Route of Administration, 2017–2027
12.3.1. Intravenous
12.3.2. Subcutaneous Injection
12.3.3. Oral
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Distribution Channel
13. Competitive Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis, by Company, 2018
13.3. Company Profiles
13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Company Financials
13.3.1.3. Growth Strategies
13.3.1.4. SWOT Analysis
13.3.2. CSL Limited
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Company Financials
13.3.2.3. Growth Strategies
13.3.2.4. SWOT Analysis
13.3.3. Pharming Group N.V.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Company Financials
13.3.3.3. Growth Strategies
13.3.3.4. SWOT Analysis
13.3.4. Ionis Pharmaceuticals, Inc.
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Company Financials
13.3.4.3. Growth Strategies
13.3.4.4. SWOT Analysis
13.3.5. BioCryst Pharmaceuticals, Inc.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Company Financials
13.3.5.3. Growth Strategies
13.3.5.4. SWOT Analysis
13.3.6. KalVista Pharmaceuticals Ltd.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Company Financials
13.3.6.3. Growth Strategies
13.3.6.4. SWOT Analysis
13.3.7. Attune Pharmaceuticals
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Company Financials
13.3.7.3. Growth Strategies
13.3.7.4. SWOT Analysis
List of TablesTable 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, by Phase II and Phase I
Table 03: Pipeline Analysis, by Preclinical Trial
Table 04: Orphan Drug Exclusivity
Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market
Table 06: Disease Overview by Type of HAE
Table 07: Reported and Estimated Cases of HAE, by Country
Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027